ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
64,700
-200 (-0.31%)
Apr 18, 2025, 3:30 PM KST
200.93%
Market Cap 3.14T
Revenue (ttm) 33.40B
Net Income (ttm) -55.53B
Shares Out 48.53M
EPS (ttm) -1,156.34
PE Ratio n/a
Forward PE 76.18
Dividend n/a
Ex-Dividend Date n/a
Volume 1,434,706
Average Volume 2,028,374
Open 65,000
Previous Close 64,900
Day's Range 62,400 - 66,100
52-Week Range 21,200 - 66,600
Beta 1.02
RSI 79.05
Earnings Date Mar 12, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.